MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

In November, AbbVie gained approval for Vyalev, a transformative therapy for treating advanced Parkinson’s disease. Studies are also ongoing to evaluate new indications for Botox and Juvederm ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after ...

Fast forward to 2024, and she confidently walked the runway at Australian Fashion Week, thanks to a groundbreaking drug trial for Vyalev. Filming a steamy scene on a sun-drenched Capri beach, Theo ...

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

Parkinson's disease—a neurological disorder of the brain that affects a person's movement—develops when the level of dopamine, a chemical in the brain that's responsible for bodily movements ...